Competing risk analysis for DSS
DSS, death, colorectal neuroendocrine neoplasms, CRNENs-specific death
LIVER METASTASIS, BRAIN METASTASIS
In the univariate competing risk analysis of DSS, factors including age, histology, grade, TNM stage, and treatment (surgery, chemotherapy, and radiation) were found to be associated with the DSS of patients with stage II-IV CRNENs. According to the multivariate analysis results, patients in grade III/IV (HR: 4.79, 95%CI: 4.27-5.31), higher TNM stage ([stage III vs stage II] HR: 2.69, 95%CI: 1.96-3.42; [stage IV vs stage II] HR: 4.96, 95%CI: 4.14-5.78), with liver metastasis (HR: 1.86, 95%CI: 1.39-2.32), and with brain metastasis (HR: 5.01, 95%CI: 4.15-5.87) had higher risk of suffering death specifically due to CRNENs. In terms of treatment, surgery can significantly reduce CRNENs-specific death (HR: 0.67, 95%CI: 0.29-1.05), but not chemotherapy or radiation (Univariate and multivariate competing risk analysis of DSS of the II-IV stage patients with CRNENs.* American Indians/Alaskan Native Americans, Asians or Pacific Islanders and Unkonwn.CRNENs, colorectal neuroendocrine neoplasms; grade: well differentiated (G I), moderately differentiated (G II), poorly differentiated (G III) and undifferentiated (G IV).